The news: Approved vaccines for infants to protect against a serious respiratory disease called RSV are facing safety concerns from federal health agency officials, according to Reuters.

• RSV drugmakers Sanofi and AstraZeneca (Beyfortus) and Merck (Enflonsia) were told last week to expect more safety questions following skepticism raised by HHS Secretary Robert F. Kennedy Jr.’s staff this summer, including reviewing previous approval studies.
• Both vaccines are approved for infants under five to eight months; Beyfortus was first to market in 2023, while Enflosia was approved in June.

Why it matters: The FDA has already changed children’s vaccine recommendations around measles, flu, and hepatitis B. Challenging approved RSV shots could signal a broader pullback on childhood immunizations.

• An estimated 58,000 to 80,000 US children younger than age 5 are hospitalized with RSV every year, per August 2024 CDC data.
• A real-world CDC study after the 2023-2024 RSV season found Beyfortus was 90% effective in preventing hospitalization in infants.
• Sanofi and AstraZeneca are marketing Beyfortus for the 2025 season, beginning in September with a campaign featuring a celebrity “mom squad” running on digital and social media.

Implications for pharma marketers: Heightened federal scrutiny adds uncertainty for RSV manufacturers at a time when the childhood vaccine environment is already polarized. RSV vaccines, which include Pfizer’s maternal vaccine Abrysvo, were hailed as major breakthroughs, and doubled-back attention from regulators complicates rollout and messaging.

Vaccine makers need to consider:

• Regulatory unpredictability. Extra safety reviews may slow the process by requiring more data, and possibly weaken provider recommendations even without formal restrictions.
• Renewed trust challenges. Technical safety questions can quickly feed anti-vaccine narratives in an already skeptical environment.
• Higher marketing stakes. Sanofi’s celebrity “mom squad” approach shows the need for trust-focused, parent-driven messaging that other manufacturers may need to emulate.